The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC

Clin Breast Cancer. 2021 Oct 25:S1526-8209(21)00301-3. doi: 10.1016/j.clbc.2021.10.007. Online ahead of print.ABSTRACTEndocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the use of molecularly targeted agents. Cytotoxic chemotherapy continues, however, to have an important role in these patients and it is important to maximize its efficacy while minimizing toxicity to optimize outcomes. This review examines current HR-positive/HER2-negative MBC clinical guidelines and addresses key questions around the use of chemotherapy in the face of emerging therapeutic options. Specifically, the indications for chemotherapy in patients with HR-positive/HER2-negative MBC and the choice of optimal chemotherapy are discussed.PMID:34844889 | DOI:10.1016/j.clbc.2021.10.007

Source: Clinical Genitourinary Cancer - November 30, 2021 Category: Cancer & Oncology Authors: Chris Twelves Rupert Bartsch Noa Efrat Ben-Baruch Simona Borstnar Luc Dirix Petra Tesarova Constanta Timcheva Lyudmila Zhukova Xavier Pivot Source Type: research